Abstract
The Czech Republic has the highest incidence of renal cell carcinoma in the world. One third of patients are diagnosed at the stage of disease generalization and another one third of patients develop metastatic disease following a primarily localized tumor.
According to the guidelines of specialist societies, first line treatment of metastatic carcinoma may include a selection of several targeted therapy agents that differ primarily in their toxic profile and that have a comparable therapeutic effect expressed as prolonged progression free survival. One of these therapeutic options is the administration ofpazopanib, a tyrosine kinase inhibitor which may be presumed o nave a better toxic profile and thus could be better tolerated by patients compared to sunitinib, according to data presented at recent specialist oncology conferences.
We present a case report of successful one year treatment with pazopanib of a seventy year old patient with a history of cardiac disease.